Kristin Kathleen Ancell

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

Richard D. Carvajal, Jeffrey A. Sosman, J. Fernando Quevedo et al. · JAMA · 2014 · 429 citations · Full text

Medicine, Oncology, Pharmacology +15

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

Megan H. Pollack, Helen Clare Dearden, K. Rapazzo et al. · Annals of Oncology · 2017 · 392 citations · Full text

Pharmacy, Immunology, Oncology +14

Hematologic Complications of Immune Checkpoint Inhibitors

Elizabeth J. Davis, Joe‐Elie Salem, Arissa Young et al. · The Oncologist · 2019 · 176 citations · Full text

Medicine, Hematology, Pharmacology +17

Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

Henry T. Quach, Anna K. Dewan, Elizabeth J. Davis et al. · JAMA Oncology · 2019 · 109 citations · Full text

Medicine, Dermatology, Oncology +17

Response to Anti–PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis

Douglas B. Johnson, Riyue Bao, Kristin Kathleen Ancell et al. · Journal of the National Comprehensive Cancer Network · 2019 · 70 citations · Full text

Medicine, Immunology, Oncology +17